SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-128927"
 

Search: onr:"swepub:oai:DiVA.org:liu-128927" > Clinical characteri...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases

Klaff, Rami (author)
Linköpings universitet,Institutionen för klinisk och experimentell medicin,Medicinska fakulteten,Region Östergötland, Urologiska kliniken i Östergötland
Berglund, Anders (author)
Eksatravagen 72, Uppsala, Sweden
Varenhorst, Eberhard (author)
Linköpings universitet,Urologi,Hälsouniversitetet,Region Östergötland, Urologiska kliniken i Östergötland
show more...
Olov Hedlund, Per (author)
Karolinska Institute Solna, Sweden
Nler, Morten J. (author)
Aalborg University Hospital, Denmark
Sandblom, Gabriel (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2015-07-14
2016
English.
In: BJU International. - : WILEY-BLACKWELL. - 1464-4096 .- 1464-410X. ; 117:6, s. 904-913
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objective To describe characteristics and quality-of-life (QoL), and to define factors associated with long-term survival in a subgroup of patients with prostate cancer with M1b disease. Patients and Methods The study was based on 915 patients from a prospective randomised multicentre trial (No. 5) by the Scandinavian Prostate Cancer Group, comparing parenteral oestrogen with total androgen blockade. Long-term survival was defined as patients having an overall survival of >= 10 years, and logistic regression models were constructed to identity clinical predictors of survival. QoL during follow-up was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - C30 version 1 (EORTC-C30) ratings. Results In all, 40 (4.4%) of the 915 men survived for >10 years. Factors significantly associated with increased likelihood of surviving for >10 years in the univariate analyses were: absence of cancer-related pain; Eastern Cooperative Oncology Group (ECOG) performance status of <2; negligible analgesic consumption; T-category of 1-2; prostate-specific antigen (PSA) level of <231 mu g/L; and a Soloway score of 1. In the multivariate analyses, ECOG performance status of <2, PSA level of <231 mu g/L, and Soloway score of 1, were all independent predictors of long-term survival. All subscales of the EORTC-C30 were higher in this group than for patients with short survival, but slowly declined over the decade. Conclusion A subgroup of patients with prostate cancer with M1b disease and certain characteristics showed a positive long-term response to androgen-deprivation therapy with an acceptable QoL over a decade or more. Independent predictors of long-term survival were identified as ECOG performance status of <2, limited extent of bone metastases (Soloway score of 1), and a PSA level of <231 mu g/L at the time of enrolment.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

prostate cancer; bone metastases; long-term survival; quality-of-life

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view